RxDoctor Payments Data

Frank Sconzo, MD

Colon & Rectal Surgery · East Patchogue, NYNPI 1952362667

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. La Jolla Pharmaceutical Company accounts for 60.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $4,270 and has fallen 98.9% since, to $47 in 2025.

$6,781in general payments, 2019–2025

Across 37 payments — averaging $183.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • La Jolla Pharmaceutical Company$4K
  • Medical Device Business Services, Inc.$2K
  • Medtronic$325
  • Johnson & Johnson$194
  • KARL Storz Endoscopy-america$150
  • Pfizer$125
  • plus $246 from 9 others

What the payments were for

  • Consulting fees$3255%
  • Speaking & faculty fees$3,74455%
  • Travel & lodging$1,32520%
  • Food & beverage$1,38820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,781 in reported general payments places this provider in the 75th percentile of 177 colon & rectal surgery providers in New York.

See all colon & rectal surgery providers in New York

Medicare billing

Part B allowed, 2024
$98,064
Medicare patients
220
Services billed
455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,536
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,866
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag14$1,671
Metronidazole18$75
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab, Suflave$20$4,20730 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$35$1,86613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 177 colon & rectal surgery providers in New York.

Other colon & rectal surgery in East Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →